The contribution of real-world evidence to cost-effectiveness analysis: case study of Dabigatran etexilate in France.

Gérard de PouvourvillePatrick BlinPierre Karam

Published in: The European journal of health economics : HEPAC : health economics in prevention and care (2019)

The reassessment of outcomes and cost data had an impact on results, improving the efficiency of Dabigatran. We identify methodological issues which should be discussed if post-launch RWE based cost-effectiveness data become a standard in HTA decision making.

Keyphrases

decision making
atrial fibrillation
electronic health record
big data
artificial intelligence
weight loss